Long -term survival achieved in Stage III melanoma with before surgery immunotherapy

Four years after pre-surgery treatment with a new combination of immune inhibitors, Nivolumab and Relatlimab, 87% of patients with Stadium III in black meant remained alive, according to new results from a study by researchers at the Cancer Center of the University of Texas MD Anderson.

Long -term monitoring data from this Phase II study, published today in Newspaper of clinical oncologyTo demonstrate this combination provides long -term benefits to patients when given before and after surgery and unique biomarkers have been identified related to better results and lower chances of relapse.

Of the 30 patients involved in the study, 80% had no recurrence of their cancer after four years. For patients who had a significant response, called a significant pathological response, from treatment when evaluated during surgery, it remained even more free of recurrence at 95%.

If immunotherapy eliminates most of the tumor before surgery, then we have adequately trained the immune system for an anti -cancer reaction, which minimizes the possibility of relapse. We encourage us with these results that show the long -term benefit of this combination and approach to our patients and the opportunity it provides to learn as much as possible about what leads this answer to treatment. “

Elizabeth Burton, Ph.D., corresponding author, Executive Director of the MD Anderson Strategic Research Development Program (Stride)

Stage III melanoma has a high risk of recurrence after surgery, stressing the opportunity to add pre-surgery or newcomer immunotherapy to shrink the tumor and promote the immune system to protect against future relapses.

Relatlimab is a LAG-3 inhibitor, an control point inhibitor approved in 2022 in conjunction with Nivolumab by the Food and Drug Administration (FDA) for patients with advanced melanoma based on the PHASE II/III clinical trial of relativity, headed by Hussein Tawbi, MD.

In this Phase II test, led by Rodabe Amaria, MD, Professor Melanoma Medical Oncology, the researchers were the first to evaluate this combination in the new active environment for a previous stage illness. The initial findings reported that this combination was safe and effective in this setting.

Due to the strong correlation with the results with a significant pathological reaction, the researchers evaluated biomarkers to better understand the factors related to treatment response.

They found that patients with high levels of pre-treatment of a biological index, called Tigit or low levels of another biomarker, called B7-H3, had the best chance of being left without relapse, emphasizing the ability to use these indicators to predict patients’ answers.

“This study highlights the enormous impact that incorporates excellent multi -scientific care with the science of the group to improve the results of patients, while promoting science and innovation. Burton said.” This is a good starting point where future ”.

Moving forward, the authors work with researchers at the James P. Allison Institute of MD Anderson to validate these biomarkers and use a spatial profile to further understand where they are and how they can affect the microenval of the volume.

This clinical trial was funded by Bristol Myers Squibb, with additional support for this study by Mon Anderson’s Moon Shots program, the National Cancer Institute (P50CA221703, P30 CA016672, UM1 TR004538 and P30 CA008748). Tawbi and Amaria were authors for this study, along with Jennifer Wargo, MD, Professor of Surgery Oncology.